Study wrapper · #991
Elamipretide: a mitochondria-targeting drug for Barth syndrome.
Villatore A, Ehle EA, Chelko SP Trends in pharmacological sciences. 2026.
DOI: 10.1016/j.tips.2026.06.011PubMed: 42448476
Editor's note
This review covers elamipretide (SS-31) for Barth syndrome, a use recently supported by regulatory approval. As a brief review it summarizes rather than generates evidence, but it centers a tracked peptide with a clear clinical narrative. Supports a measured, non-promotional writeup noting the ultra-rare indication.
Plain-language abstract
A short review discusses elamipretide (SS-31), a mitochondria-targeting peptide, in the context of Barth syndrome, a rare inherited mitochondrial disorder.
Related coverage
Weak / none
Breaking a mitochondrial danger-STING feed-forward amplifier preserves alveolar-capillary architecture and dampens interferon-chemokine signaling in acute lung injury.
Tissue & celln=——2026
Weak / none
Mitochondrial-targeted SS-31 peptide attenuates radiation-induced cardiomyocyte senescence.
Journal of radiation researchn=——2026
Weak / none
Elamipretide in pediatric Barth syndrome: from heart failure to school return.
Orphanet journal of rare diseasesn=——2026